These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 29961332)

  • 1. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
    Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
    Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD
    Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2.
    Sun B; Jia Y; Yang S; Zhao N; Hu Y; Hong J; Gao S; Zhao R
    Br J Nutr; 2019 Aug; 122(4):400-410. PubMed ID: 31204637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.
    Valenzuela R; Illesca P; Echeverría F; Espinosa A; Rincón-Cervera MÁ; Ortiz M; Hernandez-Rodas MC; Valenzuela A; Videla LA
    Food Funct; 2017 Apr; 8(4):1526-1537. PubMed ID: 28386616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
    Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
    Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
    Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
    Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
    Liu H; Zhong H; Yin Y; Jiang Z
    Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
    Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
    Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
    Pant A; Rondini EA; Kocarek TA
    Toxicol Appl Pharmacol; 2019 Feb; 365():61-70. PubMed ID: 30611723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.